About Nanobiotix

Company Description

Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges.

Nanobiotix’s novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix’s Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Year founded

2003

Served area

Worldwide

Headcount

110

Headquarters

60 Rue de Wattignies, 75012 Paris – France

Shareholder information

Shares outstanding

34,825,872

IPO

Oct. 29, 2012

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.